Clinical application and efficacy evaluation of liquid-based cytology combined with HPV testing in cervical cancer screening

To detect abnormalities in cervix cells that may result in cancer, cervical cancer screening is performed.A screening might involve testing for the human papillomavirus, cervical cytology, or both.Cervical cancer screenings need to be routine for most women.This research aimed to conduct a clinical analysis of the liquid-based cytology (LBC) cytologic assessment and highrisk human papillomavirus (HPV) utilizing Screening for cervical cancer.1000 females who visited the patient clinic as study participants were screened for this study.The traditional Pap LBC test was compared to screening with HR-HPV testing for subtypes 18 and additional HR-HPV types and the data was evaluated using SPSS.A total of 1000 women aged 20 to 40 received cervical cancer screening over the research period.600 underwent screening with LBC between 2020 and 2021 while 400 underwent screening with HR-HPV between 2021 and 2022.Referral rates for colposcopy were higher for HR-HPV testing when compared to primary LBC screening.When compared to LBC screening, the identification of CIN 3+ lesions was greater when using HR-HPV screening.In summary, primary HR-HPV screening must be taken into consideration for screening as it was linked to a greater detection rate of CIN 3+ than cytology screening.